biotech leadership Archives

We hear it all the time in biotech goal setting: “We can’t set goals until the Board signs off on our corporate strategy.”

The problem? That board meeting often doesn’t happen until February. By then, you’ve lost two of your twelve months and momentum.

At Danforth Health, we’ve worked with more than 1,8000 life science companies. One of the most common missteps we see is delaying biotech goal setting until everything is “finalized”. This hesitation leads to operational drift and signals to your team that alignment and accountability are negotiable. They aren’t.

Start Early. Adjust Later.

Even if your corporate strategy isn’t finalized yet, you can, and should, begin laying the groundwork for effective goal setting in biotech well before the calendar flips to January.

“You can always adjust. You can always modify. But if you wait to begin until everything is finalized, you’ve already fallen behind.” Danforth Advisors HR Experts

A Rolling Approach to Biotech Goal Setting

Begin in December: Host departmental and individual goal-setting sessions using current KPIs, performance metrics, and known priorities. This helps create momentum while keeping teams focused.

Use a Rolling Framework: When corporate goals are finalized post-board meeting, refine existing goals- don’t restart the process. This prevents duplication of effort and supports better alignment.

Train Managers to Guide the Process: Not everyone is naturally skilled at facilitating effective goal-setting conversations. And in biotech, where teams are lean and leaders wear many hats, that matters. Invest in manager enablement so that goal conversations are structured, consistent, and clear.

“A lot of the conversations we see around goal setting are vague. You want clarity on outcomes, not just tasks. Managers need to know how to distinguish between the two.” – Danforth Advisors HR Experts

Best Practices for Biotech Goal Setting

Use SMART Goals: Make them Specific, Measurable, Achievable, Relevant, and Time-bound. In biotech, metrics matter- especially when tied to funding, product development, and hiring plans.

Limit Company-Wide Goals to 3–5: Especially at the early stage, less is more. Trying to pursue too many priorities dilutes focus. Danforth Health consistently sees better execution when companies narrow down to a handful of core, high-impact goals.

Distinguish Goals from Tasks: A goal is a measurable outcome (e.g., “Complete IND submission by Q3”). A task is a step toward that goal (e.g., “Draft protocol outline”). Confusing the two can muddy accountability and derail timelines.

Cascade and Align: Once corporate goals are in place, ensure every department and employee understands how their work contributes to the larger mission. Alignment isn’t automatic- it’s built through communication and iteration.

What Happens After You Set Goals?

Effective biotech goal setting doesn’t stop once objectives are written down. Make it a living process:

Revisit them monthly or quarterly
Identify gaps, changing priorities, or resource constraints
Adjust without starting from scratch
Review progress transparently with leadership and staff

Need Help Setting Goals in Biotech?

At Danforth Health, we help biotech companies operationalize clarity-turning strategic priorities into measurable, achievable goals at every level. Don’t let the calendar or boardroom delay your momentum. Reach out today.

Over the past two years, the biotech sector has weathered a difficult correction. Funding constraints and pipeline reprioritizations have led to waves of layoffs, creating leaner teams across the industry. Yet even as companies downsize, the need for specialized expertise has never been greater. The result is a widening talent gap – one that threatens productivity, continuity, and innovation.

Leaders at small and mid-sized biotech companies are being forced to make tough decisions: how to preserve institutional knowledge, sustain development momentum, and remain competitive with limited internal bandwidth.

Here are five takeaways for companies navigating this new workforce landscape:

1. Prioritize Core Expertise, Outsource the Rest

Not every role needs to be rebuilt internally. Identify which functions are critical to your intellectual property, regulatory strategy, or investor value story – and consider trusted external partners for everything else. Strategic outsourcing can allow you to execute on your business strategy while preventing burnout, reducing fixed costs, and ensuring continuity through development inflection points.

2. Reassess Organizational Design for Agility

Lean doesn’t have to mean overextended. Reassess how decisions have been made and consider if a smaller team could mean a more efficient approach, where bottlenecks exist, and which functions are duplicative. Flattening structures and empowering cross-functional project leads can help maintain momentum even with smaller teams.

3. Invest in Retention – Even When You’re Cutting Costs

After layoffs, there is often undesirable attrition, and the remaining team members often carry heavier workloads and higher stress. Retention depends on transparency, recognition, and growth opportunities. Simple actions, like reviewing and updating roles and responsibilities, consistent communication about company direction, flexible work arrangements, or development stipends, can have an outsized impact on morale and loyalty.

4. Bridge Skill Gaps Through Partnerships and Interim Talent

Specialized expertise in areas like regulatory strategy, CMC, bioinformatics, and clinical operations is increasingly scarce. Interim or fractional experts can bridge capability gaps without the long-term cost of full-time hires, allowing your team to have the right level and amount of expertise as needed. If you are embracing a fractional model, look for experienced consultants or partner firms who understand biotech’s unique regulatory and operational nuances.

5. Revisit Workforce Planning Every Quarter

Embrace a just-in-time hiring model. While there is great talent in the market right now, hiring too far ahead of your needs can unnecessarily accelerate your cash burn. The market is shifting fast. What seemed essential six months ago may not be today. Building a rolling 3- to 6-month talent roadmap—aligned with your pipeline milestones and financing horizon—helps avoid reactionary hiring or deep cuts later on.

The Bottom Line

The biotech talent landscape is being reshaped in real time, but the need for great talent never goes away. In today’s environment, success will depend on strategic resourcing, organizational agility, and empathetic leadership. Companies that balance cost discipline with a thoughtful approach to people management will emerge stronger, more focused, and ready to capture opportunity as the market rebounds.

Danforth Health uniquely bridges both sides of the talent challenge — providing fractional experts to fill critical functional gaps. Our team can work with you to determine if a fractional resource is right for your business or if this is the time to invest in a full-time hire. Either way, we have the expertise and network to assess your needs, recruit the appropriate resources, and support their onboarding in a way that thoughtfully integrates them into your team quickly and efficiently.

Click here to schedule a free consultation about how we can support your talent needs.

Tag: biotech leadership

Biotech Goal Setting: Why It’s a Mistake to Wait for the Board Meeting